Interim Report January-March 2023
Record earnings and strong growth in all areas of the business January-March 2023 · Net sales totaled SEK 71,276 (32,574) thousand, with a growth rate of 119%. Growth is 107%, adjusted for currency effects. Net sales include USD 4 million in license revenues from Selecta Biosciences. Organic growth adjusted for license revenues from Selecta Biosciences is 41%, and 30% when also adjusted for currency effects. · Gross profit totaled SEK 67,098 (29,419) thousand. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 45,089 (11,717) thousand. · Operating